NCT02780128 2026-03-10
NEPENTHE
Children's Hospital of Philadelphia
Phase 1 Terminated
Clinical Trials
8 trialsNCT02513667 2023-02-03
Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT03087448 2022-12-27
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
University of California, San Francisco
Phase 1 Terminated
NCT02186821 2021-04-08
SIGNATURE
Novartis
Phase 2 Terminated
NCT02587650 2020-01-27
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
University of California, San Francisco
Phase 2 Terminated
NCT02465528 2019-12-27
Ceritinib Rare Indications Study in ALK+ Tumors
Novartis
Phase 2 Terminated
NCT02374489 2018-04-05
A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma
National Health Research Institutes, Taiwan
Phase 2 Terminated
NCT02638909 2018-04-02
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Criterium, Inc.
Phase 2 Terminated